The Canadian Institutes of Health Research has awarded RI-MUHC researchers $55 million to maximize access to and drive excellence in clinical trials. These researchers will lead or co-lead large-scale projects that will improve the development and conduct of clinical trials and expand access to experimental treatments for underrepresented communities. A couple of the projects are outlined below.
The CANadian Consortium of Clinical Trial TRAINing (CANTRAIN) project, initiated by Dr. Jean Bourbeau, will receive more than $11 over three years from the CIHR Clinical Trials Fund. This project will adopt an equitable, diversified and inclusive approach to training the professionals who conduct clinical trials in Quebec and across Canada.
ACT, the Accelerating Clinical Trials(ACT) Canada Consortium, co-chaired by Dr. Sushmita Pamidi, through which new treatments, drugs, devices and biotechnology will be tested.
Jean Bourbeau, MD, is a respirologist, director of the Centre for Innovative Medicine and senior scientist at the Translational Research in Respiratory Diseases Program at the RI-MUHC.
Sushmita Pamidi, MD, is a respirologist, scientist and associate leader of the Translational Research in Respiratory Diseases Program at the RI-MUHC.